SAR 444336
Alternative Names: IL-2 AI Synthorin; IL-2 autoimmune synthorin; IL-2 Synthorin; SAR-444336; Synthorin IL-2; THOR-809Latest Information Update: 28 Apr 2025
At a glance
- Originator Synthorx
- Developer Sanofi
- Class Anti-inflammatories; Interleukins; Recombinant proteins
- Mechanism of Action Interleukin 2 replacements; Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in France (Parenteral)
- 12 Dec 2023 Sanofi completes a phase I pharmacokinetic trial in Netherlands (SC, Injection) (NCT05876767)
- 28 Oct 2023 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)